Alliance for Pandemic Preparedness

June 14, 2021

Safety Immunogenicity and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-Administered With Seasonal Influenza Vaccines

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] As part of the Phase 3 randomized trial for the Novavax SARS-CoV-2 vaccine, a sub-study found that co-administration of an influenza vaccine resulted in no change in influenza vaccine immune response, and a slight reduction in antibody responses to the Novavax vaccine. The authors suggest that this could indicate the viability of combined vaccinations. SARS-CoV-2 vaccine efficacy in this sub-study was 87.5% compared to an efficacy in the main study of 89.8%. 

Heath et al. (June 13, 2021). Safety Immunogenicity and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-Administered With Seasonal Influenza Vaccines. Pre-print downloaded Jun 14 from https://doi.org/10.1101/2021.06.09.21258556